Somewhat Positive Press Coverage Somewhat Unlikely to Impact Grifols SA, Barcelona (GRFS) Share Price

News articles about Grifols SA, Barcelona (NASDAQ:GRFS) have trended somewhat positive on Monday, Accern Sentiment Analysis reports. The research firm rates the sentiment of press coverage by analyzing more than twenty million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Grifols SA, Barcelona earned a news sentiment score of 0.10 on Accern’s scale. Accern also gave press coverage about the biotechnology company an impact score of 47.3522691175755 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the near future.

Grifols SA, Barcelona (GRFS) traded down $0.76 during trading on Monday, reaching $22.90. The company had a trading volume of 402,386 shares, compared to its average volume of 538,404. The firm has a market capitalization of $16,155.59, a price-to-earnings ratio of 24.62, a P/E/G ratio of 1.58 and a beta of 1.10. Grifols SA, Barcelona has a 52-week low of $17.13 and a 52-week high of $25.18. The company has a debt-to-equity ratio of 1.69, a current ratio of 3.17 and a quick ratio of 1.39.

Grifols SA, Barcelona (NASDAQ:GRFS) last released its earnings results on Thursday, November 2nd. The biotechnology company reported $0.29 EPS for the quarter, meeting the Thomson Reuters’ consensus estimate of $0.29. The firm had revenue of $1.24 billion during the quarter. Grifols SA, Barcelona had a return on equity of 18.08% and a net margin of 13.16%. equities research analysts forecast that Grifols SA, Barcelona will post 1.17 EPS for the current fiscal year.

A number of research firms have recently weighed in on GRFS. BidaskClub raised Grifols SA, Barcelona from a “hold” rating to a “buy” rating in a report on Wednesday, January 10th. ValuEngine raised Grifols SA, Barcelona from a “hold” rating to a “buy” rating in a report on Friday. Zacks Investment Research raised Grifols SA, Barcelona from a “sell” rating to a “hold” rating in a report on Thursday, January 4th. UBS Group cut Grifols SA, Barcelona from an “outperform” rating to a “market perform” rating in a report on Friday, November 24th. Finally, Citigroup assumed coverage on Grifols SA, Barcelona in a research note on Tuesday, October 31st. They issued a “buy” rating for the company. One investment analyst has rated the stock with a sell rating, four have given a hold rating and four have assigned a buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and an average price target of $24.00.

COPYRIGHT VIOLATION WARNING: This story was first reported by Community Financial News and is the property of of Community Financial News. If you are accessing this story on another website, it was illegally stolen and republished in violation of United States and international copyright & trademark laws. The original version of this story can be viewed at

Grifols SA, Barcelona Company Profile

Grifols, SA, a specialty pharmaceutical company, develops, manufactures, and distributes biological medicines on plasma derived proteins in the United States, Canada, Spain, rest of the European Union, and internationally. The company specializes in providing infusion solutions, nutrition products, and medical devices for use in hospitals and clinics.

Insider Buying and Selling by Quarter for Grifols SA, Barcelona (NASDAQ:GRFS)

Receive News & Ratings for Grifols SA Barcelona Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Grifols SA Barcelona and related companies with's FREE daily email newsletter.


Leave a Reply

share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit